Published in Proc Natl Acad Sci U S A on November 25, 2003
Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A (2005) 2.80
HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. J Virol (2009) 2.03
Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol (2008) 1.83
HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts. Blood (2007) 1.83
Unconventional repertoire profile is imprinted during acute chikungunya infection for natural killer cells polarization toward cytotoxicity. PLoS Pathog (2011) 1.81
Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J Exp Med (2006) 1.72
HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of the ATR-mediated DNA damage response. PLoS Pathog (2009) 1.71
CD16- natural killer cells: enrichment in mucosal and secondary lymphoid tissues and altered function during chronic SIV infection. Blood (2010) 1.70
HLA/KIR restraint of HIV: surviving the fittest. Annu Rev Immunol (2011) 1.66
HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. Blood (2009) 1.63
Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J Virol (2005) 1.62
Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals. PLoS Pathog (2008) 1.44
Innate immune activation in primary HIV-1 infection. J Infect Dis (2010) 1.40
Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin Exp Immunol (2007) 1.38
Immunogenetics of HIV disease. Immunol Rev (2013) 1.25
Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection. J Virol (2009) 1.21
The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer-cell subsets associated with high levels of HIV-1 viremia. Blood (2009) 1.15
T-B+NK+ severe combined immunodeficiency caused by complete deficiency of the CD3zeta subunit of the T-cell antigen receptor complex. Blood (2006) 1.15
Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57. J Virol (2011) 1.14
Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells. Front Immunol (2013) 1.13
Identification of NKG2A and NKp80 as specific natural killer cell markers in rhesus and pigtailed monkeys. Blood (2005) 1.11
Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)-1 highly exposed seronegative subjects (HESN). Clin Exp Immunol (2011) 1.11
HIV infection is associated with a preferential decline in less-differentiated CD56dim CD16+ NK cells. J Virol (2009) 1.11
Involvement of activating NK cell receptors and their modulation in pathogen immunity. J Biomed Biotechnol (2011) 1.10
Identification of human NK cells that are deficient for signaling adaptor FcRγ and specialized for antibody-dependent immune functions. Int Immunol (2012) 1.08
TLR/NCR/KIR: Which One to Use and When? Front Immunol (2014) 1.03
HIV infection abrogates the functional advantage of natural killer cells educated through KIR3DL1/HLA-Bw4 interactions to mediate anti-HIV antibody-dependent cellular cytotoxicity. J Virol (2012) 1.02
Alterations in natural killer cell receptor profiles during HIV type 1 disease progression among chronically infected South African adults. AIDS Res Hum Retroviruses (2010) 1.01
Selective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killer cell innate immunity in human immunodeficiency virus/acquired immunodeficiency syndrome. Biol Psychiatry (2007) 1.00
Evasion from NK cell-mediated immune responses by HIV-1. Microbes Infect (2012) 0.99
Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. Virology (2011) 0.97
The CD85j+ NK cell subset potently controls HIV-1 replication in autologous dendritic cells. PLoS One (2008) 0.97
Changes in cytokine levels and NK cell activation associated with influenza. PLoS One (2011) 0.96
Natural killer cells that respond to human immunodeficiency virus type 1 (HIV‐1) peptides are associated with control of HIV‐1 infection. J Infect Dis (2010) 0.95
Perturbation of the natural killer cell compartment during primary human immunodeficiency virus 1 infection primarily involving the CD56 bright subset. Immunology (2009) 0.95
Immune reconstitution of CD56(dim) NK cells in individuals with primary HIV-1 infection treated with interleukin-2. J Infect Dis (2008) 0.94
MHC class I chain-related protein A shedding in chronic HIV-1 infection is associated with profound NK cell dysfunction. Virology (2010) 0.94
A Conserved HIV-1-Derived Peptide Presented by HLA-E Renders Infected T-cells Highly Susceptible to Attack by NKG2A/CD94-Bearing Natural Killer Cells. PLoS Pathog (2016) 0.93
IL-21 augments natural killer effector functions in chronically HIV-infected individuals. AIDS (2008) 0.93
Natural killer cell responses to HIV-1 peptides are associated with more activating KIR genes and HLA-C genes of the C1 allotype. J Acquir Immune Defic Syndr (2011) 0.93
Human Herpesvirus 8 (HHV8) sequentially shapes the NK cell repertoire during the course of asymptomatic infection and Kaposi sarcoma. PLoS Pathog (2012) 0.93
NKG2C+ NK cells are enriched in AIDS patients with advanced-stage Kaposi's sarcoma. J Virol (2006) 0.93
Quantity of HLA-C surface expression and licensing of KIR2DL+ natural killer cells. Immunogenetics (2012) 0.92
Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort. Oncoimmunology (2013) 0.92
Infection with Vpr-positive human immunodeficiency virus type 1 impairs NK cell function indirectly through cytokine dysregulation of infected target cells. J Virol (2008) 0.91
2B4 expression on natural killer cells increases in HIV-1 infected patients followed prospectively during highly active antiretroviral therapy. Clin Exp Immunol (2005) 0.91
Defective plasmacytoid dendritic cell-NK cell cross-talk in HIV infection. AIDS Res Hum Retroviruses (2009) 0.91
Association of activating KIR copy number variation of NK cells with containment of SIV replication in rhesus monkeys. PLoS Pathog (2011) 0.91
Substance P inhibits natural killer cell cytotoxicity through the neurokinin-1 receptor. J Leukoc Biol (2010) 0.90
Higher NK cell IFN-γ production is associated with delayed HIV disease progression in LTNPs. J Clin Immunol (2013) 0.88
Natural killer cell dysfunction during acute infection with foot-and-mouth disease virus. Clin Vaccine Immunol (2009) 0.87
NK Cell Subset Redistribution during the Course of Viral Infections. Front Immunol (2014) 0.86
Increased number and function of natural killer cells in human immunodeficiency virus 1-positive subjects co-infected with herpes simplex virus 2. Immunology (2009) 0.86
The natural killer cell interferon-gamma response to bacteria is diminished in untreated HIV-1 infection and defects persist despite viral suppression. J Acquir Immune Defic Syndr (2014) 0.86
The impact of HIV-1 infection and exposure on natural killer (NK) cell phenotype in Kenyan infants during the first year of life. Front Immunol (2012) 0.86
Innate immune natural killer cells and their role in HIV and SIV infection. HIV Ther (2010) 0.85
Downregulation of CD94/NKG2A inhibitory receptors on CD8+ T cells in HIV infection is more pronounced in subjects with detected viral load than in their aviraemic counterparts. Retrovirology (2007) 0.85
Lysis of HIV-1-infected autologous CD4+ primary T cells by interferon-alpha-activated NK cells requires NKp46 and NKG2D. AIDS (2015) 0.83
Levels of CD56+TIM-3- effector CD8 T cells distinguish HIV natural virus suppressors from patients receiving antiretroviral therapy. PLoS One (2014) 0.82
Multiparametric analysis of host response to murine cytomegalovirus in MHC class I-disparate mice reveals primacy of Dk-licensed Ly49G2+ NK cells in viral control. J Immunol (2013) 0.82
Effect of recombinant cytokines on the expression of natural killer cell receptors from patients with TB or/and HIV infection. PLoS One (2012) 0.81
Healthy Neonates Possess a CD56-Negative NK Cell Population with Reduced Anti-Viral Activity. PLoS One (2013) 0.81
Bovine leukemia virus reduces anti-viral cytokine activities and NK cytotoxicity by inducing TGF-β secretion from regulatory T cells. Immun Inflamm Dis (2016) 0.80
Functional genomics analyses of differential macaque peripheral blood mononuclear cell infections by human immunodeficiency virus-1 and simian immunodeficiency virus. Virology (2007) 0.80
Large scale analysis of phenotype-pathway relationships based on GWAS results. PLoS One (2014) 0.80
In vitro naïve T cell proliferation failure predicts poor post-immunization responses to neoantigen, but not recall antigens, in HIV-infection. Clin Immunol (2010) 0.80
NK cells and CD1d-restricted NKT cells respond in different ways with divergent kinetics to IL-2 treatment in primary HIV-1 infection. Scand J Immunol (2011) 0.79
Differential association of gene content polymorphisms of killer cell immunoglobulin-like receptors with placental malaria in HIV- and HIV+ mothers. PLoS One (2012) 0.79
HIV-associated lymphoma in the era of combination antiretroviral therapy: shifting the immunological landscape. Pathog Dis (2015) 0.79
Decreased NK Cell FcRgamma in HIV-1 infected individuals receiving combination antiretroviral therapy: a cross sectional study. PLoS One (2010) 0.78
The role of NK cells in HIV-1 protection: autologous, allogeneic or both? AIDS Res Ther (2016) 0.77
Homo-oligomerization of the activating natural killer cell receptor NKp30 ectodomain increases its binding affinity for cellular ligands. J Biol Chem (2013) 0.77
High CD56++CD16- natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort. BMC Immunol (2014) 0.76
Persistence of pathological distribution of NK cells in HIV-infected patients with prolonged use of HAART and a sustained immune response. PLoS One (2015) 0.76
Mechanisms by Which Interleukin-12 Corrects Defective NK Cell Anticryptococcal Activity in HIV-Infected Patients. MBio (2016) 0.76
Key role of human leukocyte antigen in modulating human immunodeficiency virus progression: An overview of the possible applications. World J Virol (2015) 0.76
Alcohol suppresses IL-2-induced CC chemokine production by natural killer cells. Alcohol Clin Exp Res (2005) 0.76
Host Immune Responses in HIV-1 Infection: The Emerging Pathogenic Role of Siglecs and Their Clinical Correlates. Front Immunol (2017) 0.75
Factors Associated With the Control of Viral Replication and Virologic Breakthrough in a Recently Infected HIV-1 Controller. EBioMedicine (2017) 0.75
Evaluation of Functional NK Cell Responses in Vaccinated and SIV-Infected Rhesus Macaques. Front Immunol (2016) 0.75
High number of CD56(bright) NK-cells and persistently low CD4+ T-cells in a hemophiliac HIV/HCV co-infected patient without opportunistic infections. Virol J (2013) 0.75
Study of Natural Cytotoxicity Receptors in Patients with HIV/AIDS and Cancer: A Cross-Sectional Study. ScientificWorldJournal (2016) 0.75
Alterations of the NK cell pool in HIV/HCV co-infection. PLoS One (2017) 0.75
Significant increase in cytotoxic T lymphocytes and natural killer cells by triphala: a clinical phase I study. Evid Based Complement Alternat Med (2012) 0.75
Baseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201). PLoS One (2014) 0.75
Effects on innate immunity of a therapeutic dendritic cell-based vaccine for HIV-1 infection. Viral Immunol (2012) 0.75
HIV-Specific Antibody-Dependent Cellular Cytotoxicity (ADCC) -Mediating Antibodies Decline while NK Cell Function Increases during Antiretroviral Therapy (ART). PLoS One (2015) 0.75
Natural killer cell and T-cell subset distributions and activation influence susceptibility to perinatal HIV-1 infection. AIDS (2014) 0.75
Human Leukocyte Antigen (HLA) and Immune Regulation: How Do Classical and Non-Classical HLA Alleles Modulate Immune Response to Human Immunodeficiency Virus and Hepatitis C Virus Infections? Front Immunol (2017) 0.75
Human CD56(dim)CD16(dim) Cells As an Individualized Natural Killer Cell Subset. Front Immunol (2017) 0.75
Persistence of Activated and Adaptive-Like NK Cells in HIV(+) Individuals despite 2 Years of Suppressive Combination Antiretroviral Therapy. Front Immunol (2017) 0.75
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 15.49
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science (1999) 11.04
Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature (1986) 9.73
Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol (2001) 7.07
NK cell receptors. Annu Rev Immunol (1998) 5.99
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol (1996) 4.24
Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci U S A (2003) 3.47
Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A (2003) 2.71
HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci U S A (2001) 2.54
Role of chemokines in the biology of natural killer cells. J Leukoc Biol (2002) 2.34
Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits. J Immunol (1996) 2.13
What is a natural killer cell? Nat Immunol (2002) 2.11
Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function. J Infect Dis (2003) 1.97
Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest (1998) 1.70
Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection. J Immunol (1998) 1.59
Chemokines, cytokines and HIV: a complex network of interactions that influence HIV pathogenesis. Immunol Rev (2000) 1.50
Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2002) 1.49
Deleterious effect of HIV-1 plasma viremia on B cell costimulatory function. J Immunol (2003) 1.44
Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals. J Clin Immunol (2002) 1.33
Inability of natural killer cells to destroy autologous HIV-infected T lymphocytes. AIDS (2003) 1.24
TGF beta and HIV infection. Ann N Y Acad Sci (1993) 1.15
NK cells and HIV infection: lessons from other viruses. Curr Mol Med (2002) 1.11
Normalization of natural killer cell function and phenotype with effective anti-HIV therapy and the role of IL-10. AIDS (2002) 1.05
Natural killer (NK) cell activity during HIV infection: a decrease in NK activity is observed at the clonal level and is not restored after in vitro long-term culture of NK cells. Clin Exp Immunol (1992) 1.03
Modulation of expression of the MHC class I-binding natural killer cell receptors, and NK activity in relation to viral load in HIV-infected/AIDS patients. J Med Virol (2001) 1.03
Changes in natural immunity during the course of HIV-1 infection. Clin Exp Immunol (1993) 1.02
Immune restoration after treatment of HIV-1 infection with highly active antiretroviral therapy (HAART). AIDS Rev (2002) 1.01
NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. Eur J Immunol (2002) 1.01
Distribution of the human immunodeficiency virus coreceptors CXCR4 and CCR5 on leukocytes of persons with human immunodeficiency virus type 1 infection and pulmonary tuberculosis: implications for pathogenesis. J Clin Immunol (2001) 0.91
The impact of highly active antiretroviral therapy on HIV-specific immune function. AIDS (2001) 0.86
HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication. Proc Natl Acad Sci U S A (2002) 17.22
Mesenchymal stem cells in health and disease. Nat Rev Immunol (2008) 11.14
Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis (2008) 11.01
The challenge of emerging and re-emerging infectious diseases. Nature (2004) 8.94
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
Universal voluntary testing and treatment for prevention of HIV transmission. JAMA (2009) 7.20
Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med (2008) 5.14
HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol (2008) 5.01
The 1918 influenza pandemic: insights for the 21st century. J Infect Dis (2007) 4.99
Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis (2008) 4.86
B cells in HIV infection and disease. Nat Rev Immunol (2009) 4.73
Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70
Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med (2002) 4.32
The research agenda of the National Institute of Allergy and Infectious Diseases for antimicrobial resistance. J Infect Dis (2008) 3.84
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA (2013) 3.82
An HIV vaccine--evolving concepts. N Engl J Med (2007) 3.78
HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest (2005) 3.62
Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc Natl Acad Sci U S A (2007) 3.60
The persistent legacy of the 1918 influenza virus. N Engl J Med (2009) 3.58
Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med (2003) 3.52
Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis (2007) 3.50
Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci U S A (2003) 3.47
Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood (2007) 3.38
Treatment of hepatitis C virus infection: is it time for the internist to take the reins? Ann Intern Med (2014) 3.28
Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS (2010) 3.26
The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med (2009) 3.17
Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J (2003) 3.06
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03
CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol (2007) 2.97
The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol (2008) 2.85
Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A (2005) 2.80
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood (2009) 2.75
Emerging infections: a perpetual challenge. Lancet Infect Dis (2008) 2.75
Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A (2003) 2.71
Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep (2002) 2.70
Infections caused by Scedosporium spp. Clin Microbiol Rev (2008) 2.69
Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci U S A (2004) 2.66
The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol (2004) 2.64
Evaluation of initial CD4+ T cell counts in individuals with newly diagnosed human immunodeficiency virus infection, by sex and race, in urban settings. J Infect Dis (2002) 2.57
Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A (2005) 2.55
NK cells in HIV infection: paradigm for protection or targets for ambush. Nat Rev Immunol (2005) 2.54
Influenza vaccines for the future. N Engl J Med (2010) 2.54
Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res (2012) 2.54
Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. Proc Natl Acad Sci U S A (2006) 2.54
Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol (2007) 2.50
Immunoregulatory function of mesenchymal stem cells. Eur J Immunol (2006) 2.47
Dengue and hemorrhagic fever: a potential threat to public health in the United States. JAMA (2008) 2.45
Development of effective vaccines against pandemic influenza. Immunity (2006) 2.45
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest (2011) 2.44
Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis (2011) 2.40
Pathogenic mechanisms of HIV disease. Annu Rev Pathol (2011) 2.36
Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med (2002) 2.36
The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission. PLoS Pathog (2011) 2.32
NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood (2005) 2.31
The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A (2009) 2.30
The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol (2003) 2.29
CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci U S A (2004) 2.23
Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood (2002) 2.21
Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis (2005) 2.12
What is a natural killer cell? Nat Immunol (2002) 2.11
A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. N Engl J Med (2016) 2.09
B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood (2010) 2.05
NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol (2002) 2.02
HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proc Natl Acad Sci U S A (2007) 2.01
Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol (2008) 2.01
Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J Exp Med (2004) 2.00
Previously transmitted HIV-1 strains are preferentially selected during subsequent sexual transmissions. J Infect Dis (2012) 2.00
The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood (2007) 1.99
Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function. J Infect Dis (2003) 1.97